Details

Autor(en) / Beteiligte

• Hui, Yan
• Li, Shuxin
• Zhang, Junping
• Liu, Bingcheng
• Mi, Yingchang
• Wei, Hui
• Wang, Jianxiang

Titel

Heterogeneity analysis of the CEBPAdm AML based on bZIP region mutations

Ist Teil von

• Blood science, 2023-04, Vol.5 (2), p.101-105

Ort / Verlag

Hagerstown, MD: Lippincott Williams & Wilkins

Erscheinungsjahr

2023

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Patients with double-mutated CEBPA ( CEBPA dm) AML were stratified into favorable risk group, however, few studies have investigated the heterogeneity of different CEBPA dm types in detail. In this study, we analyzed 2211 newly diagnosed AML and identified CEBPA dm in 10.8% of the patients. Within the CEBPA dm cohort, 225 of 239 patients (94.14%) presented with bZIP region mutations ( CEBPA dmbZIP) while 14 of 239 patients (5.86%) without bZIP region mutation ( CEBPA dmnonbZIP). Analysis of the accompanied molecular mutations showed statistically different incidences of GATA2 mutations between the CEBPA dmbZIP group and the CEBPA dmnonbZIP group (30.29% vs 0%). In the analysis of outcomes, patients with CEBPA dmnonbZIP were associated with shorter overall survival (OS) censored at hematopoietic stem cell transplantation (HSCT) during CR1 compared to those with CEBPA dmbZIP (hazard ratio (HR) = 3.132, 95% confidence interval (CI) = 1.229–7.979, P = .017). Refractory or relapsed AML (R/RAML) patients with CEBPA dmnonbZIP were associated with shorter OS compared to those with CEBPA dmbZIP (HR = 2.881, 95% CI = 1.021–8.131, P = .046). Taken together, AML with CEBPA dmbZIP and CEBPA dmnonbZIP showed different outcomes and might be regarded as distinctive AML entities.